Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db2664ea1258acace9a7a0550230a9db http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3f06161c8222218d91d43831cf9cc228 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0306 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y301-06004 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0058 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y301-06004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
filingDate |
2019-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c7a84ca7fcd0ea21487d2e128a7a145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5049c6ec765d78a5e2c515f4dbcf5d00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edf8c82a7f0532114be50b2e337d7c17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fa09c1366f47baa22d098d9a3d51079 |
publicationDate |
2020-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2020023857-A1 |
titleOfInvention |
Treatment of mucopolysaccharidosis iva |
abstract |
Provided herein are gene therapy methods for the treatment of mucopolysaccharidosis type IVA (MPS IVA) involving the use of recombinant adeno-associated viruses (rAAVs) to deliver human N-acetylgalactosamine-6-sulfate sulfatase (hGALNS) to the bone of a human subject diagnosed with MPS IVA. Also provided herein are rAAVs that can be used in the gene therapy methods and methods of making such rAAVs. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023077092-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021154956-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021021661-A1 |
priorityDate |
2018-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |